Dr. Peter L Greenberg M.D.?
Update this Profile
Dr. Peter L Greenberg M.D., Hematologist (Blood Specialist)
We verify the medical license of each FindaTopDoc Verified Doctor to ensure that their license is active and they are in good medical standing.

Dr. Peter L Greenberg M.D.

Hematologist (Blood Specialist) | Hematology

875 Blake Wilbur Drive Room 2335, Stanford Stanford CA, 94305
Write A Review

About

Dr. Peter Greenberg is a hematology internist practicing in Stanford, CA. Dr. Greenberg specializes in cases of suspected blood disorders when a diagnosis is unclear and further medical care is needed. Hematology internists work with other specialists such as surgeons, radiation therapists and gynecologists in order to get a better understanding on the cases. Often, patients are asked to participate in clinical research that could result in more efficient treatment methods.

Board Certification

Internal MedicineAmerican Board of Internal MedicineABIM- Hematology

Internal MedicineAmerican Board of Internal MedicineABIM- 1970

Provider Details

MaleEnglish

Expert Publications

Data provided by the National Library of Medicine

Awards

  •  1997 International Prize for outstanding research in myelodysplastic syndro 

Treatments

  • Myelodysplastic Syndromes (mds), Blood Disorders

Fellowships

  • Stanford University School of Medicine CA    1971
  • Stanford University School of Medicine,Stanford, Ca, United States   1971

Publications

  • JOURL OF CLINICAL ONCOLOGYRole of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem2013
  • PROCEEDINGS OF THE TIOL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMHematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes2013
  • JOURL OF CLINICAL ONCOLOGYRisk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma2013
  • Jourl of the tiol Comprehensive Cancer Network : JNCCNThe multifaceted ture of myelodysplastic syndromes: clinical, molecular2013
  • BLOODReduced rR expression and increased rD promoter methylation in CD342012
  • BLOODRevised Intertiol Prognostic Scoring System for Myelodysplastic Syndromes2012
  • INTERTIOL JOURL OF LABORATORY HEMATOLOGYMolecular and genetic features of myelodysplastic syndromes2012
  • CELLPersol Omics Profiling Reveals Dymic Molecular and Medical Phenotypes2012
  • JOURL OF CLINICAL ONCOLOGYMyelodysplastic Syndromes: Dissecting the Heterogeneity2011
  • JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORKMyelodysplastic Syndromes2011
  • BRITISH JOURL OF HAEMATOLOGYCurrent therapeutic approaches for patients with myelodysplastic syndromes2010
  • AMERICAN JOURL OF HEMATOLOGYA phase II intra-patient dose2009
  • J t Comp Cancer NetworkNCCN Task Force Report: Transfusion and Iron Overload in Patients with Myelodysplastic Syndromes2009
  • Jourl of the tiol Comprehensive Cancer NetworkMyelodysplastic syndromes.2008
  • Jourl of the tiol Comprehensive Cancer NetworkThe costs of drugs used to treat myelodyspl2008
  • Am J HematologyIntertiol MDS Risk Alysis Workshop (IMRAW)0
  • Eur J HaematolRelative response of patients with myelodysplastic syndromes2008
  • BloodPhase II Study of Lelidomide in Transfusion-Dependent2008
  • Clinical LeukemiaMyelodysplastic Syndromes2007
  • New Eng J MedHematologic and cytogenetic response to lelidomide in myelodysplastic syndrome with chromosome 5q2006
  • Jourl of the tiol Comprehensive Cancer NetworkMyelodysplastic syndromes clinical practice guidelines in oncology.2006
  • Jourl of the tiol Comprehensive Cancer NetworkMyelodysplastic syndromes: iron overload consequences and current chelating therapies.2006
  • BloodClinical application and proposal for modification of the Intertiol Working Group2006
  • CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGYMagement of patients with higher risk myelodysplastic syndromes2005
  • JOURL OF CLINICAL ONCOLOGYMitoxantrone, etoposide2004
  • BloodA Decision Alysis of Allogeneic Bone Marrow Transplantation for the Myelodysplastic Syndromes2004
  • J t Comprehensive Cancer NetworkNovel biospecific agents for the treatment of myelodysplastic syndromes.2003
  • ANLS OF THE RHEUMATIC DISEASESTreatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines2001
  • LANCETImplications of pathogenetic and prognostic features for magement of myelodysplastic syndromes2001
  • LEUKEMIA RESEARCHApoptosis and its role in the myelodysplastic syndromes1998
  • BLOODIntertiol scoring system for evaluating prognosis in myelodysplastic syndromes1997
  • BLOODMaintence treatment of the anemia of myelodyspl1996
  • SEMIRS IN HEMATOLOGYBiologic and clinical implications of marrow culture studies in the myelodysplastic syndromes1996
  • BloodMaintence treatment of the anemia of myelodysplastic syndromes with recombint human G1996
  • BLOODTREATMENT OF THE ANEMIA OF MYELODYSPLASTIC SYNDROMES USING RECOMBINT HUMAN GRANULOCYTE-COLONY1993
  • SEMIRS IN ONCOLOGYINVITRO MARROW CULTURE STUDIES IN THE MYELODYSPLASTIC SYNDROMES1992
  • SEMIRS IN ONCOLOGYTREATMENT OF MYELODYSPLASTIC SYNDROMES WITH HEMATOPOIETIC GROWTH-FACTORS1992
  • CANCER RESEARCHFUNCTIOL INTERACTIONS BETWEEN COLONY1990
  • Greenberg, P. L., Negrin, R., gler, A.EFFECTS OF CSFS IN PRELEUKEMIA1990
  • BLOODMAINTENCE TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES USING RECOMBINT HUMAN GRANULOCYTE1990
  • INTERTIOL JOURL OF CELL CLONINGBONE-MARROW CELL MODULATION AND INHIBITION OF MYELOPOIESIS BY LARGE GRANULAR LYMPHOCYTES AND TURAL1990
  • LEUKEMIAEFFECTS OF RECOMBINT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR AND GRANULOCYTE1990
  • Greenberg, P., Negrin, R., gler, A., Vincent, M., Donlon, T.EFFECTS OF PROLONGED TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINT HUMAN GRANULOCYTE COLONY1990
  • ANLS OF INTERL MEDICINETREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR1989
  • BLOODSELECTIVE GENERATION OF ERYTHROID BURST PROMOTING ACTIVITY BY RECOMBINT INTERLEUKIN1988
  • JOURL OF CELLULAR PHYSIOLOGYRECEPTOR-BINDING AND MITOGENIC EFFECTS OF INSULIN AND INSULIN1987
  • ACTA HAEMATOLOGICABIOLOGIC TURE OF THE MYELODYSPLASTIC SYNDROMES1987
  • JOURNAL OF CLINICAL ONCOLOGYRole of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem2013
  • PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OHematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes2013
  • JOURNAL OF CLINICAL ONCOLOGYRisk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma2013
  • Scientific ReportsSpecific plasma autoantibody reactivity in myelodysplastic syndromes2013
  • Journal of the National Comprehensive Cancer Network : JNCCNThe multifaceted nature of myelodysplastic syndromes: clinical, molecular2013
  • BLOODReduced rRNA expression and increased rDNA promoter methylation in CD342012
  • BLOODRevised International Prognostic Scoring System for Myelodysplastic Syndromes2012
  • INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGYMolecular and genetic features of myelodysplastic syndromes2012
  • CELLPersonal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes2012
  • Lab InvestigationDistinctive contact between CD34+ hematopoietic progenitors2012
  • LEUKEMIA RESEARCHTreatment of higher risk myelodyspl2012
  • JOURNAL OF CLINICAL ONCOLOGYMyelodysplastic Syndromes: Dissecting the Heterogeneity2011
  • JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORKMyelodysplastic Syndromes2011
  • LEUKEMIA RESEARCHProspective assessment of effects on iron2010
  • BRITISH JOURNAL OF HAEMATOLOGYCurrent therapeutic approaches for patients with myelodysplastic syndromes2010
  • BLOODRelationship of differential gene expression profiles in CD342009
  • BLOODTreatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte2009
  • AMERICAN JOURNAL OF HEMATOLOGYA phase II intra-patient dose2009
  • J Nat Comp Cancer NetworkNCCN Task Force Report: Transfusion and Iron Overload in Patients with Myelodysplastic Syndromes2009
  • Journal of the National Comprehensive Cancer NetworkMyelodysplastic syndromes.2008
  • Journal of the National Comprehensive Cancer NetworkThe costs of drugs used to treat myelodyspl2008
  • Am J HematologyInternational MDS Risk Analysis Workshop (IMRAW)0
  • BloodPredictive factors of response2008
  • J Clin OncolFactors affecting response2008
  • Eur J HaematolRelative response of patients with myelodysplastic syndromes2008
  • BloodPhase II Study of Lenalidomide in Transfusion-Dependent2008
  • Clinical LeukemiaMyelodysplastic Syndromes2007
  • Leukemia ResearchDefinitions and standards in the diagnosis and treatment of the myelodysplastic syndromes2007
  • New Eng J MedHematologic and cytogenetic response to lenalidomide in myelodysplastic syndrome with chromosome 5q2006
  • Journal of the National Comprehensive Cancer NetworkMyelodysplastic syndromes clinical practice guidelines in oncology.2006
  • BloodA phase II study of the farnesyltransferase inhibitor tipifarnib2006
  • Cambridge University Press, Cambridge, EnglandMyelodysplastic Syndromes: Clinical and Biological Advances0
  • Journal of the National Comprehensive Cancer NetworkMyelodysplastic syndromes: iron overload consequences and current chelating therapies.2006
  • BloodClinical application and proposal for modification of the International Working Group2006
  • CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGYManagement of patients with higher risk myelodysplastic syndromes2005
  • JOURNAL OF CLINICAL ONCOLOGYMitoxantrone, etoposide2004
  • BloodA Decision Analysis of Allogeneic Bone Marrow Transplantation for the Myelodysplastic Syndromes2004
  • LEUKEMIA RESEARCHComparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome2003
  • J Nat Comprehensive Cancer NetworkNovel biospecific agents for the treatment of myelodysplastic syndromes.2003
  • Hematology / the Education Program of the American Society of HematoloMyelodysplastic syndromes.2002
  • ANNALS OF THE RHEUMATIC DISEASESTreatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines2001
  • LANCETImplications of pathogenetic and prognostic features for management of myelodysplastic syndromes2001
  • Hematology: Basic Principles and Practice. 3rd Ed., Hoffman R, Benz E,The Myelodysplastic Syndromes , .2000
  • Forum (Genoa, Italy)Prognostic scoring systems for risk assessment in myelodysplastic syndromes.1999
  • LEUKEMIA RESEARCHApoptosis and its role in the myelodysplastic syndromes1998
  • LEUKEMIA RESEARCHBcl-2 expression by myeloid precursors in myelodysplastic syndromes1998
  • LEUKEMIA RESEARCHRisk factors and their relationship to prognosis in myelodysplastic syndromes1998
  • OncologyNCCN Practice Guidelines for Myelodysplastic Syndromes1998
  • BLOODInternational scoring system for evaluating prognosis in myelodysplastic syndromes1997
  • BLOODAltered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells1996
  • BONE MARROW TRANSPLANTATIONGM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation1996
  • BLOODMaintenance treatment of the anemia of myelodyspl1996
  • SEMINARS IN HEMATOLOGYBiologic and clinical implications of marrow culture studies in the myelodysplastic syndromes1996
  • BloodMaintenance treatment of the anemia of myelodysplastic syndromes with recombinant human G1996
  • EXPERIMENTAL HEMATOLOGYENRICHMENT OF BONE-MARROW AND BLOOD PROGENITOR (CD34(+)) CELLS BY DENSITY GRADIENTS WITH SUFFICIENT1995
  • EXPERIMENTAL HEMATOLOGYMODULATION OF APOPTOSIS IN HUMAN MYELOID LEUKEMIC-CELLS BY GM-CSF1995
  • LEUKEMIAEFFECTS OF GRANULOCYTE-COLONY1995
  • BLOODTREATMENT OF THE ANEMIA OF MYELODYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN GRANULOCYTE-COLONY1993
  • BLOODT-CELL SUBSETS AND SUPPRESSOR CELLS IN HUMAN BONE-MARROW1992
  • SEMINARS IN ONCOLOGYINVITRO MARROW CULTURE STUDIES IN THE MYELODYSPLASTIC SYNDROMES1992
  • SEMINARS IN ONCOLOGYTREATMENT OF MYELODYSPLASTIC SYNDROMES WITH HEMATOPOIETIC GROWTH-FACTORS1992
  • --Programmed cell death (apoptosis) as a mechanism for regulating haematopoietic cell population size0
  • BLOOD REVIEWSTREATMENT OF MYELODYSPLASTIC SYNDROMES1991
  • BLOOD CELLSEFFECTS OF INSULIN-LIKE GROWTH-FACTORS ON HEMATOPOIESIS1991
  • CANCER RESEARCHFUNCTIONAL INTERACTIONS BETWEEN COLONY1990
  • BLOODIMPACT OF MARROW CYTOGENETICS AND MORPHOLOGY ON INVITRO HEMATOPOIESIS IN THE MYELODYSPLASTIC1990
  • Greenberg, P. L., Negrin, R., Nagler, A.EFFECTS OF CSFS IN PRELEUKEMIA1990
  • BLOODMAINTENANCE TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN1990
  • INTERNATIONAL JOURNAL OF CELL CLONINGBONE-MARROW CELL MODULATION AND INHIBITION OF MYELOPOIESIS BY LARGE GRANULAR LYMPHOCYTES AND1990
  • LEUKEMIAEFFECTS OF RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR AND GRANULOCYTE1990
  • BLOODHEMATOPOIETIC PROGENITOR-CELL EXPRESSION OF THE H-CAM (CD44) HOMING-ASSOCIATED ADHESION MOLECULE1990
  • Greenberg, P., Negrin, R., Nagler, A., Vincent, M., Donlon, T.EFFECTS OF PROLONGED TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE1990
  • ANNALS OF INTERNAL MEDICINETREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY1989
  • BLOODSELECTIVE GENERATION OF ERYTHROID BURST PROMOTING ACTIVITY BY RECOMBINANT INTERLEUKIN1988
  • JOURNAL OF CELLULAR PHYSIOLOGYRECEPTOR-BINDING AND MITOGENIC EFFECTS OF INSULIN AND INSULIN1987
  • ACTA HAEMATOLOGICABIOLOGIC NATURE OF THE MYELODYSPLASTIC SYNDROMES1987
  • New Engl J MedGranulopoiesis in acute myeloid leukemia and preleukemia1971

Experience & Accolades

  • Member1979 - 2005Head, Hematology Section, VA Palo Alto Health Care System
  • Member1978 - 1979 Acting Chief, Medical Service, VA Palo Alto Health Care System
  • Director 1998 - 2013 Stanford MDS Center
  • Member2009 - 2013 Coordinator, International Working Group for Prognosis in MDS
  • Chair1997 - 2013 National Comprehensive Cancer Network Myelodysplasitic Syndromes Practice Guidelines Panel

Dr. Peter L Greenberg M.D.'s Practice location

Peter Greenberg

875 Blake Wilbur Drive Room 2335, Stanford -
Stanford, CA 94305
Get Direction
New patients: 650-725-8355
Fax: 650-723-1269

Dr. Peter L Greenberg M.D.'s reviews

(0)
Write Review

Recommended Articles

  • Multiple Myeloma: What is Autotransplantation?

    During a stem cell transplantation or autotransplantation, the patient receives high chemotherapy dosage which is sometimes done to the entire body to get rid of the cells that are in the bone marrow (including the myeloma cells). Afterwards, the patient receives new stem cells to form...

  • 5 Foods to Eat When you Have Anemia

    Anemia refers to a state where the body witnesses a decrease in the number of circulating red blood cells causing symptoms like paleness of skin, lethargicness, headache and chest pain. Termed as the most common blood disorder, anemia is strictly not a disease, but a disorder that is often a...

  • Causes, Treatment, and Prevention of Petechiae

    Petechiae are tiny dots that appear as red, brown, or purple in color beneath the skin. They are usually seen in clusters on the stomach, buttocks, arms, and legs. However, they may also appear inside the mouth or on the eyelids. Petechiae may indicate different conditions, which can range from...

  • Why is Cord Blood Banking Important?

    Cord blood banking is the method of preserving cord blood, which is blood taken from the umbilical cord after the delivery. Cord blood contains hefty amounts of stem cells, which are potential life-saying cells for numerous diseases. Collecting cord blood is a painless procedure, and is considered...

  • What Is Leukopenia: Symptoms and Causes

    What is leukopenia?Leukopenia is a condition in which abnormally low white blood cells are circulating in the blood. This condition can be diagnosed using a blood test called complete blood count (CBC). A normal white blood cell count is usually between 3,500-11,000 WBCs per microliter. People...

  • What Is Bone Marrow? - Diseases, Symptoms, and Transplant

    What Is Bone Marrow?Bone Marrow is the flexible tissue present in the interior of the bones. Constituting only about 4% of the body mass in the human body, Bone marrow is responsible for 500 billion blood cells every day. It is also a key component of the lymphatic system as it produces lymphocytes...

Nearby Providers

See all nearby providers

Nearest Hospitals

STANFORD HEALTH CAREl

300 PASTEUR DRIVE STANFORD CA 94305

Head north on Blake Wilbur Drive 383 ft
Turn left onto Welch Road 1270 ft
Turn left onto Pasteur Drive 55 ft
You have arrived at your destination, on the left

1708 ftSee direction

MENLO PARK SURGICAL HOSPITALl

570 WILLOW ROAD MENLO PARK CA 94025

Head north on Blake Wilbur Drive 357 ft
Turn right onto Welch Road 1607 ft
Turn left onto Quarry Road 1048 ft
Turn right onto Arboretum Road 1357 ft
Turn left onto Palm Drive 1622 ft
Continue straight onto University Avenue 851 ft
Continue onto University Avenue 3088 ft
Turn left onto Middlefield Road 2535 ft
Turn right onto Willow Road 3026 ft
Turn right 219 ft
You have arrived at your destination, on the right

3.0 miSee direction

LUCILE SALTER PACKARD CHILDREN'S HSP AT STANFORDl

725 WELCH ROAD PALO ALTO CA 94304

Head north on Blake Wilbur Drive 357 ft
Turn right onto Welch Road 788 ft
Turn right 348 ft
Turn left 69 ft
You have arrived at your destination, on the left

1562 ftSee direction